Kornimate/medical-research-clean huggingface dataset:
grateful strides toward physical activity and well-being for black breast cancer survivors

Conditions: Cancer Survivors; African Americans; Women; Psychology, Positive; Cardiometabolic Syndrome; Exercise; Feasibility Studies; Breast Neoplasm Female

Summary: this pilot study will assess the feasibility of a gratitude intervention to promote physical activity, and well-being and positively impact biomarkers of health among older african american breast cancer survivors. the intervention will also include a goal-setting component to promote exercise readiness and examine the cultural phenomena of the superwoman schema among black women.

in this pilot feasibility study, the overall aims are: aim 1. assess the feasibility and acceptability of a gratitude journaling intervention using a pilot randomized controlled trial (rct) design over eight weeks. we hypothesize that among the 28 participants 1) at least 80% of the participants will report the intervention to be acceptable, 2) biomarker collection will be completed in at least 80% of the surveys and the retention rate will be 80% in each group, and 3) physical activity, health markers, gratitude, well-being, and distress will improve over time. aim 2. describe distributions of outcome variables and effect size for the gratitude journaling intervention on dispositional gratitude, spiritual well-being, psychological distress, exercise readiness, mental and health behaviors in african american/black women (superwoman schema), and inflammatory biomarkers from baseline to post-intervention.

Eligibility criteria:
inclusion criteria: * self-report as aa or black * english speaking * history of bc (stage i-iv); 3 months to 6 years post-adjuvant chemotherapy * participants on hormonal therapies or her-2 therapy are acceptable exclusion criteria: * self-reported regular meditation or gratitude practices (more than once a week for at least a month) * meeting the cdc's physical activity guidelines (at least 150 min of moderate-intensity aerobic physical activity or 75 min of vigorous-intensity physical activity, or an equivalent combination each week)

Keywords: african american women breast cancer survivorship gratitude cardiometabolic syndrome geriatrics physical activity
chidamide combined with cyclophosphamide, prednisone, thalidomide in treatment of fragile patients with relapse/refratory peripheral t cell lymphoma

Conditions: Relapse/Refratory Peripheral T Cell Lymphoma

Summary: the purpose of this study is to investigate efficacy and safety of chidamide combined with cyclophosphamide,prednisone,thalidomide in treatment of fragile patients with relapse/refratory peripheral t cell lymphoma :a phase ii,single-arm,open-label, muti-center study

chidamide is a new histone deacetylase inhibitor and shows anti-tumor activity in relapse/refratory peripheral t cell lymphoma.cyclophosphamide,prednisone,thalidomide(cpt) is an oral combination regimen for lymphoma patients who can not stand the standard chemotherapy. the investigators therefore design this open-label,phase ii, single-arm trial to investigate the efficacy of chidamide combined with cpt in treatment of fragile patients with relapse/refratory peripheral t cell lymphoma primary outcome measures: • overall response rate secondary outcome measures: * duration of response * progression free survival * overall survival enrollment:45 study start date: august 2016 primary completion date: march 2018

Eligibility criteria:
inclusion criteria: 1. histologically confirmed peripheral t cell lymphoma,exclude nk/t cell lymphoma 2. relapse or refractory to at least one prior therapy(chemotherapy or stem cell transplantation) 3. can not 4. age between 18 and 75, both gender 5. ecog ps 0-1 6. peripheral anc \>1.5\*109/l; platelet \>70\*109/l; hb≥ 90g/l 7. anticipated survival ≥ 3 months 8. no chemotherapy ,radiotherapy and stem cell transplantation within 4 weeks before inclusion 9. sign in informed consent form, adherence to the study visit schedule and other protocol requirements exclusion criteria: 1. pregnant women or women in suckling period or with potentia generand but not willing to take contraceptives 2. new york heart association class iii or iv cardiac failure; or history of following disease in past 6 months: acute coronary syndrome, acute heart failure, severe ventricular arrhythmia 3. poor hepatic function, defined as total bilirubin more than 1.5 fold of upper normal level, alt, ast more than 2 fold of upper normal level or more than 5fold of upper normal level with hepatic involvement;poor renal function, defined as serum creatinine more than 1.5 fold of upper normal level 4. cns or meningeal involvement 5. intervention on myelosuppression within7 days before inclusion 6. patients with active bleeding 7. major surgery within three weeks before inclusion 8. positive hiv, syphilis,hcv, or hbv virus load(hbv dna)\> 1×105 copies/ml; 9. any psychological conditions which may disturb consent. 10. in any conditions which investigator considered ineligible 11. known sensitivity or allergy to investigational product.

Keywords: relapse/refratory peripheral t cell lymphoma chidamide cyclophosphamide、prednisone、thalidomide(cpt)
response assessment during mr-guided radiation therapy for glioblastoma

Conditions: Glioblastoma Multiforme

Summary: the study seeks to assess the response of glioblastoma multiforme to treatment using weekly low field (0.35 t) mr-images of the brain at a mridian® linac system during standard radiotherapy at the same system. a total of 20 patients in a single arm will be recruited for this investigation. the imaging data will be used to evaluate the change in tumor volume over the course of the treatment and to perform radiomics in order to investigate the possibility of response prediction using these images. in order to assure sufficient image quality, prior to the main investigation, a group of up to 20 volunteers has mr scans taken with identical sequences to the main study phase.


Eligibility criteria:
inclusion criteria patients: subjects fulfilling all of the following criteria are eligible for the study: * informed consent as documented by signature according to swiss law and ich/gcp regulations before any trial specific procedures (appendix i informed consent form) * histologically confirmed diagnosis of gbm * indication for fractionated radiation therapy for gbm * age: ≥ 18 years old * gender: any * karnofsky performance status ≥60 * patients who are willing and able to comply with scheduled visits, treatment, and other trial procedures exclusion criteria * the presence of any one of the following criteria will lead to exclusion of the subject: * previous cranial radiation therapy * contraindications to mr examinations, e.g., non-compatible implantable device or metallic foreign bodies * inability to complete mr examination due to claustrophobic anxiety * women who are pregnant or breast feeding, * intention to become pregnant during the course of the study * lack of safe contraception, defined as: female subjects of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases. female subjects who are surgically sterilized / hysterectomized or post-menopausal for longer than 2 years are not considered as being of child bearing potential. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, diabetes, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia * known or suspected non-compliance, drug or alcohol abuse * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the subject * participation in another study with investigational drug within the 30 days preceding and during the present study * enrolment of the investigator, his/her family members, employees and other dependent persons
precise: a prospective, multi-center evaluation of the accuracy of a novel continuous implanted glucose sensor

Conditions: Diabetes Mellitus

Summary: the purpose of this clinical investigation is to evaluate the accuracy of the senseonics continuous glucose monitoring system (senseonics cgm system) measurements when compared with reference standard measurements (ysi glucose analyzer). the investigation will also evaluate safety of the senseonics cgm system usage, while in the clinic and during home use.


Eligibility criteria:
inclusion criteria: subjects meeting all of the following inclusion criteria will be included in this study: 1. males and females ≥18 years of age 2. clinically confirmed diagnosis of diabetes mellitus for a duration of 1 year and uses insulin therapy for their diabetes management (including subjects on insulin pump therapy) 3. subject has signed an informed consent document and is willing to comply with protocol requirements exclusion criteria: subjects meeting any of the following exclusion criteria will be excluded from this study: 1. history of severe hypoglycemia in the last 6 months prior to study start, defined as hypoglycemia resulting in loss of consciousness or seizure 2. diabetic ketoacidosis in the past 6 months 3. any condition preventing or complicating the placement, operation or removal of the sensor including upper extremity deformities or skin condition. 4. any medical condition or illness that in the judgment of the investigator might interfere with the procedures, results or compliance during the course of this investigation, or increase the risk of induced hypoglycemia or repeated blood testing including significantly impaired hepatic function and renal failure 5. known microvascular (diabetic) complications, including active proliferative diabetic retinopathy or macular edema, active non-proliferative retinopathy, diabetic nephropathy including active retinopathy 6. hematocrit \>50% or \<30% 7. females lactating or pregnant or intending to become pregnant during the course of the investigation 8. a condition requiring or likely to require magnetic resonance imaging
quantitative evaluation of muscle stiffness in neurological patients with muscle overactivity

Conditions: Muscle Spasticity

Summary: objective: 1. to investigate reliability, validity and responsiveness of shearwave elastography (swe) to assess muscle stiffness of overactive upper or lower limb muscles in different angle joint positions in patients with neurological condition 2. to investigate the relationship between muscle stiffness measured by swe and by myotonpro 3. to investigate the correlation between muscle stiffness measured by swe and clinical outcomes methods: each patient will be assessed three times: two times at an interval of 15 minutes on the same day and one time at an interval of one week at the same time of the day. the following measurements will be made at each evaluation: swe, myotonpro, clinical evaluation. swe and mytotonpro will be taken at different angle joint position. outcomes: muscle stiffness measured by swe and myotonpro at different angle joint positions, and clinical evaluation (passive range of motion, modified ashworth scale, tardieu scale, fuglmeyer) hypothesis: swe is a valid, reliable, and resposive method to assess muscle stiffness in neurological population with muscle overactivity. the results of swe will be correlated with the results of myotonpro and with clinical outcomes.


Eligibility criteria:
inclusion criteria: * age \> 18 years * hemiparesia/-plegia following neurological condition (tbi, stroke,...) * \> 3 months after injury * muscle overactivity in lower limb exclusion criteria: * other neurological or orthopaedic conditions involving the affected limb * aphasia or major cognitive impairment limiting functional assessment * botulinum toxin injection in the last 3 months * previous treatment of muscle overactivity with surgical procedures.

Keywords: spasticity sonoelastography
effects of bariatric surgery on cardiac and vascular structure and function in obesity

Conditions: Bariatric Surgery

Summary: this is a prospective cohort study which aims to explore the effect of bariatric surgery on cardiac and vascular structure and function in obesity. enrolled patients will receive the following examinations before surgery and 3,6,12 month after the bariatric surgery: 24-h central and brachial ambulatory blood pressure monitoring, pwv, echocardiography, vascular endothelial function, hemodynamic including cardiac output and peripheral vascular resistance and so on. we compare these data before and after surgery in order to evaluate effectiveness of bariatric surgery in the cardiac and vascular structure and function.

the including citeria: 1)15-65 years old; 2) indication for asian bariatric surgery (i.bmi≥32.5 or 27.5≤bmi\<32.5 with obesity-related comorbidities ) ;3) available for inspection and therapeutic schedule; 4) available for follow up. the excluding cteria: 1)over 65 years old; 2)myocardial infarction, angina pectoris and ischemic stroke during the previous month;3)congestive heart failure class iv based on the new york heart association classification; 4) malignancy or any other condition with poor prognosis; 5) serious pulmonary and renal dysfunction; 6) gastric disease; 7) poor compliance 8) incomplete clinical data .after enrollment, every patient will receive a question-based interview to obtain medical history and the following examinations and tests: anthropometric parameters measurement including body height, weight, waist circumference, hip circumference and so on; blood routine tests and biochemical tests. every patient needs to be assessed before surgery and at 3,6,12 month by 24-h central and brachial ambulatory blood pressure, pwv, echocardiography, vascular endothelial function, cardiac output and peripheral vascular resistance. we compare these data before and after surgery in order to evaluate effectiveness of bariatric surgery in the vascular structure and function.

Eligibility criteria:
inclusion criteria: * 15-65 years old * conformed indication of asian bariatric surgery (i.bmi≥32.5 or 27.5≤bmi\<32.5 with obesity-related comorbidities ) * available for inspection and therapeutic schedule * available for follow up exclusion criteria: * over 65 years old * myocardial infarction, angina pectoris and ischemic stroke during the previous month * congestive heart failure class iv based on the new york heart association classification * malignancy or any other condition with poor prognosis * serious pulmonary and renal dysfunction * gastric disease * poor compliance * incomplete clinical data

Keywords: cardiac and vascular structure and function
a study of nonoxynol-9 (n-9) and hiv infection

Conditions: HIV Infections

Summary: the purpose of this study is to see if nonoxynol-9 (n-9) gel used in the vagina can prevent the spread of hiv. most of the people with hiv in the world today live in southern africa. because this population is not likely to use condoms, an hiv-prevention method that women can control is needed. n-9 used in the vagina may help prevent the spread of hiv and other sexually transmitted diseases.

intravaginal application of n-9 may help protect women from hiv and other std infection. low rates of condom use in sub-saharan african populations, which constitute the majority of hiv infections, dictate the need for prophylactic methods women can control. this trial will be conducted in zimbabwe and malawi. the phase iii trial is preceded by a 2-week safety and acceptability pilot study to determine the extent of genital irritation caused by n-9 and the placebo. following the pilot study and prior to screening for enrollment in the phase iii trial, potential volunteers will participate in a 2-month behavioral counseling program that will encourage the use of condoms. only participants who decide they cannot or will not be consistent condom users are enrolled in the main study. study participants are given n-9 gel or placebo to use each time they have vaginal sexual intercourse for 18 to 36 months. participants have a follow-up evaluation once a month; a pelvic exam and blood tests are performed every third month.

Eligibility criteria:
inclusion criteria volunteers may be eligible if they: * are hiv-negative. * are sexually active and expect to have vaginal intercourse at least twice a week during the study. * are willing to keep a diary of their sexual behavior and n-9 use. * are willing to have regular clinic visits including pelvic exams. * are at least 18 years old. * are female. exclusion criteria volunteers will not be eligible if they: * have had a child or an abortion in the past 42 days. * are allergic to latex or n-9. * have genital sores. * have syphilis, chlamydia, gonorrhea, or trichomoniasis. * are enrolled in another study for a product like n-9. * expect to use another vaginal product other than n-9 during the study. * are pregnant.

Keywords: nonoxynol
role of the environment and endocrine disruptors in child cryptorchidism

Conditions: Cryptorchidism

Summary: cryptorchidism is the most frequent congenital defect of the male newborn. it requires surgery in childhood, increases the risk of fertility disorders and cancer. as a major public health objective, it's the subject of numerous recommendations. its frequency is increasing in some countries faster than a single genetic cause could not explain it. it may occurs in a geographic cluster. the cause of cryptorchidism involves genetic, hormonal and environmental factors. animal studies suggest that endocrine disruptors interfere with fetal testicular migration. the aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.

cryptorchidism is the most frequent congenital defect of the male newborn. it requires surgery in childhood, increases the risk of fertility disorders and cancer. as a major public health objective, it's the subject of numerous recommendations. its frequency is increasing in some countries faster than a single genetic cause could not explain it. it may occurs in a geographic cluster. the cause of cryptorchidism involves genetic, hormonal and environmental factors. animal studies suggest that endocrine disruptors interfere with fetal testicular migration. the aim of the study is to find out if some environmental exposition may be associated with cryptorchidism.

Eligibility criteria:
inclusion criteria: - parents of male children from the neonatal period to 18 years of age (during surgery) with cryptorchidism exclusion criteria: * parents of children without endocrine disease. (adrenal, hypothalamic-pituitary, phosphocalcic, thyroid, diabetes, etc.) * parents of children without an associated genital or urinary defect (hypospadias, micropenis, renal and bladder abnormalities) * testicular ectopia (testis outside of normal migration path) * anorchidism and evanescent testicles, united or bilateral * abnormalities of the abdominal wall (laparoschisis, omphalocele, prune belly) * cryptorchidism integrating in the context of a polymalformative syndrome, including neurological.

Keywords: cryptorchidism environmental exposition endocrine disruptors
living donor uterus transplantation between identical twins

Conditions: Absolute Uterine Factor Infertility; Cervical Cancer

Summary: living donor uterus transplantation between identical twins, with ivf before and et several months after transplantation. the donor should have completed childbirth.

living donor uterus transplantation between identical twins, with ivf before and et several months after transplantation. the donor should have completed childbirth.

Eligibility criteria:
inclusion criteria: * age below 40 years * absolute uterine factor infertility * bmi\<30- exclusion criteria: * systemic disease

Keywords: uterus, transplantation, infertility, twin
impact of the cycle ergometer in muscle strength and pulmonary function in patients in hemodialysis

Conditions: Chronic Renal Disease; Renal Dialysis

Summary: muscle strength can be measured by dynamometry, but the investigators did not find in the literature the study of this technique in the quadriceps of patients with chronic kidney disease on hemodialysis. analyze training impact conducted by cycle ergometer in quadriceps muscle strength in patients with chronic kidney disease during hemodialysis. this study will be a prospective, randomized. inclusion of 46 patients followed by the dialysis unit of a university hospital, over 18 years, of both genders who underwent hemodialysis for more than six months and signed the consent form and enlightened. patients will be divided into two groups: intervention (n = 23) and control (n = 23). all will be evaluated for demographics and quadriceps strength given by standardization of technique, with hard and windy belt. the control group will be reassessed after two months of the initial assessment, since the intervention group held two months of training in hemodialysis a physical therapy protocol with the cycle ergometer.


Eligibility criteria:
inclusion criteria: * patients aged over 18 years * performing hd over six months * clinically stable * patients no diagnosis of lung disease * neurological or mioarticular previous or current and agreed to participate in the study and signed informed consent and informed exclusion criteria: * patients undergoing elective surgery or emergency six months before or during the performance of the protocol * cardiac decompensation * used continuous or nocturnal oxygen * patients using bracing of the lower limbs.

Keywords: muscle strength muscle strength dynamometer chronic renal disease exercise physical therapy modalities